Sept 29 (Reuters) – Metsera Inc: * METSERA REPORTS POSITIVE PHASE 2B RESULTS FOR FIRST- AND BEST-IN-CLASS ULTRA-LONG ACTING GLP-1 RA CANDIDATE MET-097I, ENABLING RAPID TRANSITION INTO PHASE 3 * METSERA INC – MET-097I SHOWS 14.1% WEIGHT LOSS AFTER 28 WEEKS * METSERA INC – MET-097I SHOWS CLASS-LEADING TOLERABILITY IN TRIALS * METSERA INC – DATA SUPPORTS PHASE 3 INITIATION IN LATE 2025 Source text: Further company coverage: ;))
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
The stock market is becoming a more popular investment option for people throughout India. Digital…
By Foo Yun Chee BRUSSELS, Feb 6 (Reuters) - TikTok was charged on Friday with…
BEIJING, Feb 6 (Reuters) - Tesla is operating an artificial intelligence training centre in China…
SINGAPORE/LONDON, Feb 6 (Reuters) - Bitcoin broke back above $65,000 on Friday, as a global…
By Danielle Broadway and Rollo Ross LOS ANGELES, Feb 6 (Reuters) - Actor Margot Robbie…
Feb 6 (Reuters) - Amazon shares dropped 8% in premarket trading on Friday after the…